Growth and Geographic Variation in Hospitalizations with Resistant Infections, United States, 2000–2005
Marya D. Zilberberg , Andrew F. Shorr, and Marin H. Kollef
Author affiliations: EviMed Research Group, LLC, Goshen, Massachussetts, USA (M.D. Zilberberg); University of Massachusetts, Amherst, Massachusetts, USA (M.D. Zilberberg); Washington Hospital Center, Washington, DC, USA (A.F. Shorr)Barnes Jewish Hospital, St. Louis, Missouri, USA (M.H. Kollef);
Figure. Population incidence of component resistant infections in the United States, by census region, 2000–2005. A) Clostridium difficile–associated disease; B) methicillin-resistant Staphylococcus aureus; C) vancomycin-resistant enterococcus; D) Pseudomonas aeruginosa; E) Candida spp.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.